New study tracks PNH patients in china to uncover disease patterns
NCT ID NCT06154512
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed study followed 724 people in China with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Researchers aimed to better understand how the disease progresses and how patients respond to different treatments, including the newly available drug eculizumab. The study collected data on symptoms, complications like blood clots and kidney failure, and treatment patterns to improve future care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could provide a clearer picture of how PNH progresses in Chinese patients and how well current treatments work in the real world.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly test new therapies. Results may not apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Hefei, Anhui, 230002, China
-
Research Site
Beijing, Beijing Municipality, 100000, China
-
Research Site
Beijing, Beijing Municipality, 100044, China
-
Research Site
Guangzhou, Guangdong, 510080, China
-
Research Site
Guangzhou, Guangdong, 510180, China
-
Research Site
Guangzhou, Guangdong, 510515, China
-
Research Site
Nanning, Guangxi, 530021, China
-
Research Site
Guiyang, Guizhou, 550004, China
-
Research Site
Shijiazhuang, Hebei, 050000, China
-
Research Site
Harbin, Heilongjiang, 150001, China
-
Research Site
Zhengzhou, Henan, 450003, China
-
Research Site
Zhengzhou, Henan, 450052, China
-
Research Site
Zhengzhou, Henan, 463599, China
-
Research Site
Wuhan, Hubei, 430000, China
-
Research Site
Wuhan, Hubei, 430030, China
-
Research Site
Changsha, Hunan, 410005, China
-
Research Site
Changsha, Hunan, 410008, China
-
Research Site
Nanjing, Jiangsu, 210029, China
-
Research Site
Nantong, Jiangsu, 226001, China
-
Research Site
Xuzhou, Jiangsu, 221002, China
-
Research Site
Nanchang, Jiangxi, 330006, China
-
Research Site
Nanchang, Jiangxi, 330008, China
-
Research Site
Changchun, Jilin, 130021, China
-
Research Site
Shenyang, Liaoning, 110001, China
-
Research Site
Jinan, Shandong, 250000, China
-
Research Site
Qingdao, Shandong, 266000, China
-
Research Site
Zibo, Shandong, 255090, China
-
Research Site
Linyi, Shangdong, 276034, China
-
Research Site
Shanghai, Shanghai Municipality, 200040, China
-
Research Site
Shanghai, Shanghai Municipality, 200336, China
-
Research Site
Taiyuan, Shanxi, 030000, China
-
Research Site
Xi’an, Shanxi, 710061, China
-
Research Site
Xi’an, Shanxi, 710068, China
-
Research Site
Chengdu, Sichuan, 610041, China
-
Research Site
Chengdu, Sichuan, 610072, China
-
Research Site
Tianjin, Tianjin Municipality, 300020, China
-
Research Site
Tianjin, Tianjin Municipality, 300052, China
-
Research Site
Tianjin, Tianjin Municipality, 300190, China
-
Research Site
Kunming, Yunnan, 650034, China
-
Research Site
Hangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A pill that could replace infusions for a rare blood disease?
- Every-8-Week shot could simplify PNH treatment
- Real-World test: can a targeted drug keep PNH in check for years?
- New transplant method aims to reduce complications in bone marrow failure patients
- No treatment, just observation: large study looks at PNH blood cells
- New hope for rare blood disorder: Long-Term study of XH-S003 underway